In addition, high concentrations of IL-10 are observed in patients with Stage II and IV melanomas and contribute to the downmodulation of antitumor responses [11], while abnormally high concentrations of IL-6 are associated with a poor response and outcome and contribute to the development and progression of early-stage melanoma [12–14]. This evidence concerns the gene IL6 and melanoma.